Montelukast Ratiopharm (Montelukast Sodium)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This inhibition prevents leukotrienes D4, C4 and E4 from binding, which reduces bronchoconstriction, vascular permeability, and eosinophilic inflammation in the airways, thereby improving breathing and decreasing allergic inflammation.

The appropriate dose of Montelukast Ratiopharm is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of disease, and response to therapy. No specific dosing regimen is provided here; patients should follow the prescriber’s instructions and the product label.

Safety data for Montelukast during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Montelukast Ratiopharm. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic rhinitis. Unlike bronchodilators, it does not provide immediate relief of acute bronchospasm.

Montelukast Ratiopharm should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

The medication is taken orally as a tablet. Patients should swallow the tablet whole with water, and it may be taken with or without food. It is not intended for use as a rescue medication during an acute asthma attack.

Serious risks include neuropsychiatric events such as mood changes, agitation, or suicidal thoughts, as well as severe allergic reactions like rash, angioedema, and rare skin conditions such as Stevens‑Johnson syndrome. Hepatic dysfunction, although uncommon, may also occur and requires monitoring of liver function if clinically indicated.

Montelukast should be avoided in individuals with known hypersensitivity to the drug or any of its excipients. It is not suitable for treating acute asthma attacks, and patients with severe hepatic impairment should use it only under close medical supervision.